Bone regeneration is one of the major focus points in the field of regenerative medicine. A well-known stimulus of bone formation is bone morphogenetic protein-2 (BMP-2), which has already been extensively used in clinical applications. We investigated the possibility of achieving osteogenic differentiation both in vitro and in vivo as a result of prolonged presence of BMP-2 using plasmid DNA-based gene therapy. By delivering BMP-2 cDNA in an alginate hydrogel, a versatile formulation is developed. High transfection efficiencies of up to 95% were obtained in both human multipotent stromal cells (MSCs) and MG-63 cells using naked DNA in vitro. Over a period of 5 weeks, an increasing amount of biologically active BMP-2 was released from the cells and remained present in the gel. In vivo, transfected cells were found after both two and six weeks implantation in naked mice, even in groups without seeded cells, thus indicating in vivo transfection of endogenous cells. The protein levels were effective in inducing osteogenic differentiation in vitro, as seen by elevated alkaline phosphatase (ALP) production and in vivo, as demonstrated by the production of collagen I and osteocalcin in a mineralised alginate matrix.
Introduction
Bone regeneration is one of the major focus points within the field of regenerative medicine. To create bone tissue and augment defects, many strategies have been used, such as different cell based strategies, material development and growth factor delivery (Khan et al., 2008; Arthur et al., 2009 ).
An important growth factor in bone tissue engineering is bone morphogenetic protein 2 (BMP-2), member of the transforming growth factor  (TGF-) superfamily. BMP-2 is involved in committing multipotent stromal cells (MSCs) towards the osteogenic lineage and known to induce new bone formation (Riley et al., 1996) . Both in vitro and in vivo BMP-2 has shown strong osteoinductive activity. However, large amounts of rhBMP-2 protein are administered clinically for an osteogenic effect mainly due to fast degradation by proteinases. Animal studies have shown a half-life of 7-16 min systemically, and up to 8 days locally when implanted on a collagen sponge (Poynton and Lane, 2002) . The possible negative side effects for patients due these high doses of BMP-2 may result in vertebral osteolysis, ectopic bone formation, radiculitis and cervical soft tissue swelling (Shimer et al., 2009) .
BMP-2 gene therapy is an alternative that might be able to overcome the use of high doses of BMP-2, because when applied to cells a relatively sustained delivery of protein can be achieved (Southwood et al., 2004) . Gene therapy can be performed by viral or non-viral DNA delivery. Non-viral has several advantages over viral gene therapy, the latter one resulting in high transfection efficiencies but associated with problems such as immunogenicity, virus-dependent recombination risks and the protein expression can exceed the timeframe required for bone defect healing (Luo and Saltzman, 2000; Louise, 2006; Pietersz et al., 2006) . Non-viral gene delivery is considered much safer and usually provides a transient expression of the desired gene. However many approaches result in a low transfection efficiencies. Therefore much effort is invested into the development of an efficient nonviral gene delivery method, with the use of various transfection agents (Pelled et al., 2010) . Particularly well studied are liposomes, phospholipid bilayer vesicles which can easily merge with the cell membrane to deliver encapsulated plasmid DNA (Audouy et al., 2002; Dass, 2004; Ma et al., 2007) .
Another carrier for gene delivery, which is compatible with simultaneous cell seeding, is alginate hydrogel. Alginate is an anionic linear copolymer of -Dmannuronic acid and -L-glucuronic acid residues that gelates with bivalent cations like Ca 2+ (Kong et al., 2008) .
F Wegman et al. BMP-2 plasmid DNA for bone regeneration
It is FDA approved, non-toxic, biocompatible and extensively used in the food and drug industry. It has been used as a vehicle for plasmid DNA in the form of nanoparticles or combined with other hydrogels (Krebs et al., 2010; Park et al., 2007) and was applied in bone tissue engineering applications both in vitro and in vivo (Stevens et al., 2005; Hunt and Grover, 2010) . This makes alginate very suitable both as gene activated matrix (GAM), and for cell seeded constructs. Our aim is to develop an injectable hydrogel for bone regeneration, containing different biological components, i.e., cells and BMP-2 cDNA, which are beneficial for bone formation in a specific setting. The present study investigates the transfection efficiency of epitope-tagged BMP-2 plasmid DNA in primary human MSCs and the MG-63 cell line in alginate, and the amount of protein produced and released from the gel in vitro as well as its bioactivity. To investigate the contribution of each of the components to scaffold performance, the components are tested separate and combined. A cell-free construct was included to investigate whether resident cells at the implantation site could express functional BMP-2 from the GAM.
Materials and Methods

Alginate gel
Autoclaved high-viscosity non-medical-grade alginate powder (International Specialty Products, ISP, Memmingen, Germany) was dissolved at a concentration of 20 mg/ml in alpha minimum essential medium (-MEM; Gibco, Breda, The Netherlands). The gel was polymerised by adding an equal volume of 100 mM autoclaved CaCl 2 supplemented with 10 mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.4 (Gibco) for 10 min. Ca-solution was then replaced by 1 ml culture medium.
Cell culture MG-63 cells (osteosarcoma cell-line, ATCC #CRL-1427; ATCC, Wesel, Germany) were cultured in proliferation medium consisting of Dulbecco's modified Eagle's Medium (Gibco) supplemented with 15% (v/v) newborn calf serum (Gibco), 100 U/ml penicillin and 100 g/ml streptomycin (Gibco).
Human MSCs were isolated from bone marrow, aspirated from the iliac crest or acetabulum of patients after their informed consent and collected in heparin coated tubes. The mononuclear fraction was isolated using Ficoll density gradient centrifugation. The MSCs are isolated by adherence to tissue culture plastic, cultured in aMEM, supplemented with 10% (v/v) foetal calf serum (Cambrex, Charles City, IA, USA), 100 U/ml penicillin, 100 g/ml streptomycin, 0.2 mM L-ascorbic acid-2-phosphate (AsAP) (Sigma-Aldrich, St. Louis, MO, USA) and 1 ng/ ml FGF-2 (R&D Systems, Minneapolis, MN, USA).
Goat MSCs were isolated similarly from bone marrow (BM), aspirated from the iliac wings of Dutch milk goats and cultured in MEM (Gibco), supplemented with 15% (v/v) foetal calf serum (Cambrex), 100 U/ml penicillin, 100 g/ml streptomycin and 2 mM L-glutamine (Glutamax, Gibco). All cells were maintained at 37°C and 5% CO 2 in a humidified incubator.
Transfection procedures
For expression of BMP-2 the plasmid pcDNA3.1/His/ hBMP-2 was used, in which full-length human recombinant BMP-2 is in frame preceded by a 18 nucleotide polyhistidine region (His tag). This tag is used to detect transfected cells and discriminate between endogenous BMP-2 and BMP-2 produced as a result of transfection. During secretion of BMP-2 from cells, the tag may be removed together with the signal sequence.
Plasmid DNA (0-50 g/ml of pcDNA3.1/His/hBMP-2 or pEGFP-N1(BD Biosciences, Franklin Lakes, NJ, USA))/ Lipofectamine2000 (Invitrogen, Breda, The Netherlands) complexes were prepared according to the manufacturer's instructions. Per sample, the DNA, either or not complexed with liposomes and 10 6 trypsinised cells was mixed with 50-100 l of alginate hydrogel (20 mg/ ml). This gel mixture was polymerised by adding 100-200 l CaCl 2 /HEPES solution. After 10 min, supernatant was removed and replaced with culture medium. The gels were cultured at 37°C and 5% CO 2 in a humidified incubator for up to 5 weeks before analysis of gene expression. For preparation of the in vivo implants, see below.
FACS analysis of BMP-2, ALP and GFP
Constructs of 100 l gel containing plasmid DNA (pcDNA3.1/His/hBMP-2) and 10 6 cells were depolymerised using citrate buffer (150 mM NaCl, 55 mM sodium citrate and 20 mM EDTA in H 2 O) for 15 min at 37°C. Cells were counted and 90-110% of the seeded cells were retrieved. Cells were pelleted and fixed in 4% (v/v) formalin (Clinipath, Duiven, The Netherlands) in PBS for 10 min. All subsequent washing steps were done with PBS/ 1% (w/v) BSA. The cells were washed with PBS/BSA three times and permeabilised with 0.1% (v/v) Triton-X100 (Fluka, Zwijndrecht, The Netherlands) in PBS for 10 min. The cells were washed again and incubated with 2 g/ml anti-His (recognizing His-tagged BMP-2) antibody (Genscript, Piscataway, NJ, USA) in PBS/BSA for 1 h at room temperature (RT). Control samples were incubated with a mouse isotype-matched control IgG (2 g/ml) (Dako, Glostrup, Denmark). After antibody incubation, cells were washed with PBS/BSA and incubated in the dark with the secondary antibody goat-anti-mouseAlexa488 (Invitrogen), diluted to 20 g/ml in PBS/BSA for 30 min at RT. After secondary antibody incubation cells were washed and taken up in PBS/BSA and analysed for green fluorescence by FACS Calibur. For ALP analysis the same procedure was used, with the primary antibody B4-78-C (Developmental Studies Hybridoma Bank of Iowa, Iowa City, IA, USA) diluted 1:100 in PBS/BSA and incubated for 1 h at RT, followed by incubation in the dark for 30 min at RT with the secondary antibody goat-antimouse-PE (Southern Biotech, Birmingham, AL, USA), diluted to 0.25 g/ml in PBS/BSA. For GFP transfected cells, a similar cell isolation from gel was performed and cells were analysed for GFP intensity at day 7 (optimal expression of GFP in alginate) using the FACS Calibur. BMP-2 plasmid DNA for bone regeneration BMP-2 ELISA Constructs of 100 l gel were cultured for up to 5 weeks and medium (2 ml) was changed weekly. The collected medium was stored at -20°C. Gel samples were prepared by depolymerising alginate with citrate buffer for 15 minutes at 37°C. Cells were centrifuged and the supernatant containing the dissolved protein was stored at -20°C. The ELISA (Quantikine #DBP200 from R&D Systems) was performed on thawed samples following the standard protocol.
Preparation in vivo implants
Six different constructs of 300 l alginate (10 mg/ml) gel each were constructed and polymerised with 1 ml of 100 mM autoclaved CaCl 2 , supplemented with 10 mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.4 (Gibco), for 10 min. One group consisted of only alginate, one group contained 3 g of His/BMP-2 plasmid DNA in alginate, four groups consisted of alginate with 3 g His/BMP-2 plasmid DNA combined with 3 million MSCs from 4 different donors. The latter four contained cells from two human MSC donors, or two goat MSC donors. The gels were implanted immediately after polymerisation.
Animals and implantation
18 female nude mice (Hsd-cpb:NMRI-nu, Harlan, Boxmeer the Netherlands) were anaesthetised with 1.5% isoflurane, after which the implants were placed in 4 separate subcutaneous dorsal pockets per mouse (n=6 per group / time point). The animals were postoperatively treated with the analgesic buprenorphine (0.05 mg/kg, sc; Temgesic, Schering-Plough/Merck, Whitehouse Station, NJ, USA) and housed together at the Central Laboratory Animal Institute, Utrecht University. Experiments were conducted with the permission of the local Ethical Committee for Animal Experimentation and in compliance with the Institutional Guidelines on the use of laboratory animals.
Explantation and embedding
Two and six weeks after implantation the constructs were retrieved to analyse transfection, osteogenic differentiation and alginate properties in vivo. Samples were fixed overnight in 4% (v/v) formalin containing 100 mM CaCl 2 and processed for 5 M thick paraffin sections through alcohol dehydration series.
Histology
To analyse the alginate properties in vivo and investigate blood vessel formation, haematoxylin/eosin (HE) stainings were performed on all samples. Samples were scored on morphology, calcification and blood vessel ingrowth by two observers. A scale of 0-2 was applied; 0 indicating absence of the readout parameter, 1 for some morphology changes, calcification or blood vessel presence, and 2 for significant/abundant presence. To detect His/BMP-2-transfected cells in the implants, anti-His immunohistochemistry was performed. Sections were permeabilised with Triton X-100 and blocked in 3% H 2 O 2 for 10 min and 5% BSA for 30 min. Antigen retrieval steps were performed using 1 mg/ml pronase and 10 mg/ml hyaluronidase for 30 min each. Sections were subsequently incubated with 5 g/ml biotinylated anti-His antibody (Genscript, Piscataway, NJ, USA, A00613) for 1 h and as second antibody 3.3 g/ml streptavidin/ horseradish peroxide (HRP) was used. For collagen I, a similar protocol was performed using rabbit-anti-collagen I primary antibody (Abcam, Cambridge, UK; Ab34710) at 3.3 g/ ml and a goat-anti-rabbit-streptavidin/HRP (Invitrogen, 624320)) secondary antibody at 6.6 g/ml. For osteocalcin, a similar protocol was performed using a rabbit-antiosteocalcin primary antibody (Alexis ALX-210-333; now Thermo Fisher Scientific, Waltham, MA, USA) at 2 g/ ml and a goat-anti-rabbit-streptavidin/HRP (Invitrogen) secondary antibody at 6.6 g/ml. All stainings were developed with diaminobenzidine (DAB) and Mayer's haematoxylin was used for counterstaining. A double staining was also performed using the same primary antibodies and concentrations but with fluorescent secondary antibodies. First the collagen I antibody was added to samples for 1 h and after several wash steps the matching goat-anti-rabbit-Alexa488 (Invitrogen, A52700) at 13.3 g/ml was incubated. Then 5 g/ml biotinylated anti-His antibody was added for 1 h, followed by antibiotin streptavidin/Alexa594 (Molecular Probes, Eugene, OR, USA; S11227) at 6.6 g/ml for 30 min. All antibodies were diluted in PBS/BSA.
Von Kossa staining
Sections were deparaffinised and incubated with a 1% (w/ v) silver nitrate solution (Fisher Scientific) under a 60-100 W light bulb for 1 h. After washing with distilled water, unreacted silver is removed by 5% (w/v) sodium thiosulphate solution for 5 min. Slides were counterstained with nuclear Fast Red.
Alizarin Red staining
Sections were covered for 1-2 min with 2% (w/v) Alizarin Red (Merck, Darmstadt, Germany) and 0.5 % (v/v) ammonium hydroxide in distilled water, final pH 4.0. After incubation sections were washed with distilled water and mounted in Depex.
Goldner's trichrome staining Sections were deparaffinised and incubated with haematoxylin (Weigert's) for 5 min. Sections were washed with tap water for 5 min and incubated with Goldner's 1 solution, containing 0.2% (v/v) glacial acetic acid, 0.033% (w/v) acid fuchsine and 0.13% (w/v) Ponceaux de xilidine (Fluka), for 30-45 min. After rinsing with 1% (v/v) acetic acid, sections were stained with Orange G (Fluka, 75380) for 7 min and washed again with 1% acetic acid. Sections were counterstained with Light green (Sigma-Aldrich, L5382) for 7 min and after rinsing with 1% acetic acid were dehydrated and mounted in Depex.
Safranin O staining
Sections were deparaffinised and incubated with haematoxylin (Weigert's) for 5 min. After washing in running tap water, sections were dipped in distilled water and counterstained in 0.4% (w/v) Fast Green solution.
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Sections were rinsed in 1% (v/v) acetic acid until colour no longer runs and counterstained again in freshly prepared 0.125% (w/v) Safranin O (Merck) staining. After short dehydration protocol, sections were mounted in Depex.
Statistics
The statistical significance of differences between experimental groups in Figure 5 was assessed using a Fisher exact test for presence/absence of collagen I. Multiple comparisons were generated using a Bonferroni correction to calculate the p-values. A p-value of <0.05 was considered significant.
Results
We developed an alginate gene delivery system for use with osteoblasts and their precursors, including MSCs. To show that cell transfection in alginate is an effective method, the tracer gene enhanced green fluorescent protein (EGFP) was transfected in hMSCs or MG-63 cells, either or not after complexation with liposomes. After 7 days, the transfected cells and untransfected controls were isolated from the alginate and analysed for GFP expression. On DAPI counterstained cytospins, the positive cells were scored under a fluorescence microscope, resulting in transfection efficiencies ranging from 35-50% (Fig. 1A,  B) . For further quantification, FACS analysis was performed on transfected and untransfected cells. Cells were analysed for their fluorescence intensity level; the cells were considered transfected at a fluorescence intensity level that excluded 95 % of the untransfected cells. To compare the average amount of protein produced/cell between different groups, the mean fluorescence intensity (MFI) was analysed. For GFP this resulted in a MFI of 156-157 compared to 25 for the control (Fig. 2A) . The transfection efficiency was confirmed for both the liposome-complexed group and the naked plasmid DNA group. Safranin O staining after 6 weeks on hMSC+BMP-2 DNA seeded group, glucosaminoglycans are stained in red, Fast Green counterstaining, (F) Collagen I immunostaining after 6 weeks on hMSC+BMP-2 DNA seeded group. Collagen I in brown, methylene blue counterstaining, (G) Immunolocalisation of osteocalcin after 6 weeks in control group, (H) Osteocalcin staining after 6 weeks on hMSC+BMP-2 DNA seeded group. Positive cells stained brown.
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Transfections using the His/BMP-2 cDNA were similarly performed on MG-63 cells. Immunocytochemistry on cytospun cells transfected with or without lipofectamine-complexed plasmid DNA was performed with an antibody against the His-tag preceding the BMP-2 sequence (Fig. 1D) to discriminate between cells producing endogenous BMP-2 and transfected cells. The same cells stained negative using an isotype-matched control antibody (Fig. 1E) , whereas untransfected cells also remained unstained (Fig. 1F) . MG-63 cells and human and goat MSCs showed high transfection efficiencies, as shown by FACS analysis of His/BMP-2. The efficiency ranged from 64% up to 95% with a MFI of 643-713 compared to 38 in the control, consistent in both the liposomecomplexed and the naked DNA group (Fig. 2) .
To determine the optimal DNA concentration for BMP-2 with and without liposome complexation, hMSCs and MG-63 cells were transfected with different plasmid DNA concentrations ranging from 0.008 to 5 g DNA/gel (100 l). We also performed a FACS analysis of the His-BMP stained cells, which showed little differences in transfection efficiencies and expression levels between all different concentrations (results not shown). Even the lowest concentration tested resulted in significant expression of BMP-2. We also could not find a consistent positive effect of liposome complexation in all concentrations.
To determine BMP-2 levels released by the cells and the duration of production, alginate constructs with His/ BMP-2 plasmid DNA and MG-63 cells (Fig.3) or hMSCs (3 timepoints, results not shown) were cultured for a period up to 5 weeks. The culture medium was collected on a weekly basis and the cultured gels were depolymerised to determine the amount of BMP-2 associated with the gel by ELISA. This revealed a weekly increase of BMP-2 levels in the medium and a much higher weekly increase of BMP-2 in the gel (Fig.3) , indicating that the bulk of the produced BMP-2 remained in the gel. The complexation of DNA with liposomes did not have a further additional effect on the amount of released BMP-2.
To evaluate the biological activity of the produced BMP-2, enzymatic stainings on cell monolayers and FACS analyses of gel samples were performed for the early osteogenic marker alkaline phosphatase. Monolayers of MG-63 cells and goat-and human MSCs were transfected with the BMP-2 cDNA and either cultured in expansion medium, or cultured in routine osteogenic differentiation medium to compare the signal. As a negative control, untransfected cells were cultured in expansion medium. In both positive controls and in the BMP-2 transfected group red staining revealed the production of ALP after a week, while the unstimulated cells remained negative (Fig.  4B) . Similar results were found for MG-63 cells in gel samples which were analysed by FACS using an anti-ALP antibody. The BMP-2 transfected cells even showed a higher increase in MFI (212) than the positive control, cultured in osteogenic differentiation medium (OM) (MFI=178) compared to untransfected cells cultured in expansion medium (EM) (MFI=72), and the transfected cells stained with an isotype-matched control antibody (MFI=100) (Fig 4A) .
To investigate whether transfection in vivo would take place and is able to induce osteogenic differentiation, we implanted gel samples subcutaneously in immunodeficient mice. Analysis of the histological sections after an implantation period of either 2 or 6 weeks showed that in vivo, transfection in alginate was successful as shown by immunohistochemistry on the BMP-2 coupled His-tag. In both the human-and goat MSC seeded groups, numerous positive BMP-2 transfected cells could be found at both the 2 and 6 weeks time points (Fig 1G, H) . The samples that received BMP-2 plasmid DNA, but were cell-free, also expressed the transgene (Fig 1H) . At 2 weeks, 4/6 samples and at 6 weeks 5/6 samples stained positive for His-tagged BMP-2. This means that resident mouse cells are able to take up the plasmid DNA from the constructs and express it. This proves that transfection in vivo occurs. To determine whether the expressed levels of BMP-2 are sufficient to induce osteogenic differentiation, immunohistochemistry on collagen I was performed (Fig.  5) . At two weeks, none of the groups had produced large amounts of collagen I but some staining was visible, mainly in one of the hMSC donors. At 6 weeks, differences between the groups with and without BMP-2 plasmid DNA were far more evident. The groups receiving plasmid DNA showed significantly more collagen I production than the control group without BMP-2 DNA (p< 0.05). With the exception of hMSC donor 2, in all the groups in which plasmid DNA was combined with seeded cells, we found the significant highest amount of collagen I staining (p<0.05) compared to non-seeded groups (Fig. 5) . To investigate whether the cells expressing the plasmid DNA are also the cells that produce collagen I, or that neighbouring cells are also osteogenically induced, we performed a double staining for both His-tagged BMP-2 and collagen I (Fig. 6) . The results show that the His/BMP-2 and collagen I staining are present within the same regions in the implants, but only in a few cells co-localise. This suggests that the majority of cells differentiating towards the osteogenic linage do so through a paracrine mechanism (Fig. 6) .
To look at alginate morphology changes, HE stained sections were scored for degradation or calcification of the gel, and blood vessel formation. It appears that the gels were slowly degraded, leaving remnants of calcified material, interleaved with ingrown highly vascularised tissue. All of these aspects were found in the implants but occurred independent of the cell type or presence of DNA (Table 1) . Alizarin red and von Kossa staining of the samples also confirmed that almost all of the alginate implants calcify between 2 and 6 weeks of implantation, which could contribute to the osteogenic potential of the implants (Fig. 7) . The alginate implants also contains connective tissue as shown in green by a Goldner's trichrome staining but no highly cellularised tissue like osteoid, which would be indicated in red (Fig. 7) .
At 6 weeks however, cartilaginous tissue is present in the human MSC seeded group as shown by the cell cluster morphology, collagen matrix surrounding the cells and the heavy glycosaminoglycan (GAG) staining, indicated in red by a Safranin O staining (Fig. 7) .
Discussion and Conclusions
This study investigates the possibility of creating injectable bone tissue engineering constructs by transfecting cells with BMP-2 plasmid DNA in alginate hydrogel. Both goat and human MSCs and MG-63 cells were found to be capable of efficiently expressing BMP-2 from plasmid DNA and show a sustained release of relevant levels bioactive BMP-2. In vitro, results from MG-63 cells were shown because these are fully differentiated osteoblasts, which is a relevant cell type for bone tissue engineering. Besides MG-63 cells, human MSCs were used because they are one of the most interesting candidates for translation towards a clinical application. Goat MSCs were used because goat is a relevant and widely-used large animal model in bone tissue engineering. Gene therapy based on non-viral plasmid DNA is pursued by many groups because of reportedly low immunogenicity, transient expression without genetic recombination, and the production of large protein quantities at low cost. However, non-viral gene therapy is also known to have variable and low transfection efficiencies (Lam and Dean, 2010) . Most groups transfecting in alginate also report low transfection efficiencies and do not comment on the amount of protein produced by their constructs (Sone et al., 2002; Higashi et al., 2004) .
Our results demonstrate that the combination of plasmid DNA with alginate hydrogel however, induces high transfection efficiencies with different constructs, at different DNA concentrations in different cell types. The alginate incorporation might be an important factor in the mechanism behind these successful naked DNA transfections. Two possible explanations for high transfection efficiencies can be considered. The first theory describes DNA uptake via calcium phosphate precipitation. The alginate gels are polymerised by a 100 mM calciumchloride solution. This is a 50-100 times higher concentration of calcium than in the bloodstream or culture medium. Combined with phosphates, calciumphosphate/ DNA co-precipitates might be formed, inducing DNA uptake into the cells (Graham and van der Eb, 1973; Jordan et al., 1996; Chenuet et al., 2008) . Macropinocytosis, a different transfection method, transfers naked DNA into the cell, mediated by proteoglycans and other proteins present in culture medium (Wittrup et al., 2007) . In the context of alginate, we did not observe a clear additive effect from the use of liposomal transfection agent, even though literature describes this as an even more successful transfection method than the use of calcium phosphate precipitation (Somasundaram et al., 1992) . Normally the positively charged liposome complexes make it easier for DNA liposome complexes to access the negatively charged cell membrane (Clements et al., 2007) . The sugar chains of alginate however, might neutralise the effect of liposome complexation on the cell membrane. Even though an optimum for both naked and complexed DNA was expected to be within the range of 5 to 0.008 g/gel, titration of plasmid DNA in the context of alginate revealed that the transfection remains successful at both high or very low DNA concentrations.
An increased release of BMP-2 protein production over a period of 5 weeks was found by ELISA analysis. This was a surprising result, considering the transient nature of non-viral transfections (Stiehler et al., 2006) . Since not only culture medium samples were collected but BMP-2 levels were also measured in the depolymerised alginate, we found that a large percentage of the produced protein is contained in the gel. This probably creates a release system in which protein is produced by the transfected cells and retained in the gel. Degradation of the gel the protein then mediates its release into the medium over time which could be favourable in vivo since BMP-2 protein in the bloodstream has a half-life of several minutes. Cells might also be able to retain the plasmid DNA for several weeks, especially if little cell division takes place (Hengge et al., 2001; Wolff and Budker, 2005) .
When investigating whether osteogenic differentiation could be induced by BMP-2 transfection, the expression of early osteogenic marker ALP both on monolayers and in cells from depolymerised gel was determined. The level of ALP expression in BMP-2 transfected cells cultured in Scoring of transfected cells, alginate properties, blood vessels and collagen I (n=6 per group) of the in vivo samples after 2 and 6 weeks, see M&M for details. Sections were scored by two independent observers. * indicates 1 missing sample.
BMP-2 plasmid DNA for bone regeneration EM was similar to that in the positive control group cultured in ODM containing the osteogenic dexamethasone (Duarte et al., 2009) . Based on this assay, we conclude that BMP-2 produced from plasmid DNA transfected cells is at least as effective as ODM in directing stem cells into early osteogenic differentiation. We found that transfection is not only possible in vitro but also in vivo. Transfected cells were found in all groups containing BMP-2 plasmid DNA, either combined with or without human and goat MSCs, at both the 2 and 6 weeks time points. This means that the delivered BMP-2 plasmid DNA is also available for resident cells to take up and produce BMP-2, creating an opportunity to design an off-the-shelf construct without seeded cells. This could overcome several problems such as the risks involved in bone marrow aspirations, or the costs and time involved with culturing stem cells. Similar to the in vitro experiments, osteogenic differentiation also occurs in the in vivo implanted samples, demonstrated by collagen I and osteocalcin staining in the groups containing BMP-2 plasmid DNA, whereas little collagen I and osteocalcin staining is visible in the control group without seeded cells and plasmid DNA. This is in accordance with several studies in which implanted plasmid DNA induces differentiation (Bonadio et al., 1999) . This makes it plausible that the induction of collagen I and osteocalcin expression is the result of the BMP-2 transfection. During the implantation period in mice, no bone was formed. This might be explained by the timing of the BMP-2 release, which might be slower compared to other studies (Hosseinkhani et al., 2007; Krebs et al., 2010) . A large amount of produced BMP-2 is retained in the alginate and will not be accessible for the cells until the alginate degrades sufficiently. After 6 weeks, we still found patches of alginate present in the implants. It is possible that at later time points bone could be found, since the alginate calcifies between week 2 and week 6, providing a much more favourable surrounding to deposit bone on for differentiated osteoblasts. In a goat model, in which constructs similar to the ones described here were implanted in the muscle, abundant bone was formed after a longer implantation period (Wegman et al., in preparation) .
Remarkably, cartilaginous tissue was formed in the human MSC seeded group. MSCs are known to be able to produce bone via the endochondral bone route, so it would be interesting to see whether the cartilage is eventually mineralised and replaced by bone (Gawlitta et al., 2010) .
Another explanation for the lack of bone tissue could be that the concentration of produced BMP-2 is insufficient to induce bone formation. The amount of produced BMP-2, as determined from the in vitro study is in the range of ng, whereas the dosage used in the clinic is in the range of mg (McKay et al., 2007) . And even though large doses are used in the clinic, those are considered supraphysiological, and possibly harmful (Shields et al., 2006) . Alginate is more and more used as a delivery vehicle for BMPs and turned out to be a good matrix for osteogenic differentiation and reportedly for bone formation (Stevens et al., 2005) . As seen in the histological stainings, blood vessel ingrowth necessary for oxygen and nutrient delivery to the cells is efficient, and it calcifies in vivo, creating suitable mineralised matrix for cartilage and eventually bone formation.
Another interesting result is the fact that we found hardly any transfected cells which also produced collagen I. It is possible that other cells surrounding the implants e.g. macrophages take up the plasmid DNA in their attempt to engulf the alginate samples. These cells might then become BMP-2 producing cells, attracting and differentiating nearby osteogenic precursors, but are probably not BMP-2 responsive. This could explain the presence of limited numbers of transfected cells, which are themselves differentiating towards the osteogenic linage.
In summary, the use of gene therapy in bone tissue engineering to deliver osteogenic factors like BMP-2 has several advantages over the use of rhBMP-2 protein. Not only does it overcome the problems of short half-life and instability of BMP-2 resulting in the administration of supra-physiological protein dosages, but in some cases it can also result in more and better bone formation than the administration of rhBMP-2 (Gazit et al., 1999; Kofron and Laurencin, 2006; Pelled et al., 2010) .
We developed an economical, efficient non-viral BMP-2 gene delivery method by combining alginate with osteogenic cells and BMP-2 plasmid DNA. The alginate hydrogel serves multiple roles as an injectable scaffold, but also functions as a transfection agent and release system, releasing protein for at least 6 weeks. The produced BMP-2 protein has been proven to be biologically active and present at an effective dose to induce early osteogenic differentiation, but not yet bone formation by both human and goat MSCs and MG-63 cells in vitro and in vivo. Based on these results we conclude that after optimisation, this alginate-based gene delivery system might be a promising new development in the field of bone regeneration.
